The biotech continues to embrace artificial intelligence (AI) technology, which is heartening for investors. It owns and manages an AI developer, InstaDeep. Showing their approval, those market ...

BioNTech share performance snapshot BioNTech (NasdaqGS:BNTX) has seen mixed share price moves recently, with a small 1 day decline, a gain over the past week, a loss over the past month, and a ...

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.

Citing four unnamed people "familiar with the situation," this effort will be based on findings that were apparently filed with the federal government's Vaccine Adverse Event Reporting System. The ...

The average fair value estimate for BioNTech has been trimmed slightly, moving from $139.98 to $139.51, signaling only a modest reset in price targets. Bullish and bearish analysts are reading this ...

BioNTech SE (NASDAQ:BNTX) is one of the best stocks to buy and hold for the next 6 months. On February 2, research firm Leerink Partners downgraded BioNTech SE (NASDAQ:BNTX) to a Market Perform from ...

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...

BioNTech (NASDAQ:BNTX) pushed back on speculation Thursday that Pfizer (NYSE:PFE) may be preparing to unload its stake in the company, emphasizing that the two firms’ long-running alliance remains ...

BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...